XML 36 R27.htm IDEA: XBRL DOCUMENT v3.20.4

Related Party Balances and Transactions

9 Months Ended

Sep. 30, 2020

Related Party Transactions [Abstract]

Related Party Balances and Transactions

21. Related Party Balances and Transactions

The table below sets forth the major related parties and their relationships with the Group as of December 31, 2019 and September 30, 2020:

Name of related parties		Relationship with the Group
Everest		Controlled by the ultimate controlling party of a principal shareholder of the Group
Tasly Pharmaceutical Group Co., Ltd.		Controlled by the ultimate controlling party of a principal shareholder of the Group
CMAB Biopharma (Suzhou) Inc.		Controlled by the ultimate controlling party of a principal shareholder of the Group
I-Mab Biopharma (Hangzhou) Co., Limited		Subsidiary of the Group before September 15, 2020; Affiliate of the Group after September 15, 2020

Details of related party balance as of December 31, 2019 and September 30, 2020 are as follows:

Ordinary Shares to be issued to Everest*

		As of December 31,				As of September 30,
		2019				2020
		RMB				RMB				US$ (Note 2.5)
Everest (Note 16)			258,119				—				—

Loans to an affiliate

		As of December 31,				As of September 30,
		2019				2020
		RMB				RMB				US$ (Note 2.5)
I-Mab Hangzhou (Note(i))			—				52,000				7,659

Note(i): In July 2019 and July 2020, I-Mab Shanghai provided an interest free loan to I-Mab Hangzhou of RMB2,000 and RMB50,000 respectively to finance I-Mab Hangzhou’s operation. These loans were repaid in November 2020.

Details of related party transactions for the nine months ended September 30, 2019 and 2020 are as follows:

Receipt of CRO services—recognized in research and development expenses

		Nine Months Ended September 30,
		2019				2020
		RMB				RMB				US$ (Note 2.5)
Tasly Pharmaceutical Group Co., Ltd.			5,590				—				—

Receipt of research and development funding

		Nine Months Ended September 30,
		2019				2020
		RMB				RMB				US$ (Note 2.5)
Everest (Note 16)			52,207				—				—

Project development fee – recognized in research and development expenses

		Nine Months Ended September 30,
		2019				2020
		RMB				RMB				US$ (Note 2.5)
CMAB Biopharma (Suzhou) Inc.			—				690				102

X

- References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

+ Details

Name:	us-gaap_RelatedPartyTransactionsDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration